oasis 1 trial oral semaglutide 50 mg obesity lancet 2023 Orforglipron, an Small-Molecule GLP-1 Receptor Agonist for Treatment ADA 2023: “An explosion” of

Final Takeaway Choosing between these two peptides comes down to what fits your goals, your schedule, and your comfort level

& Das, S

Can be combined with other weight loss treatments for added effectiveness

While Wegovy carries warnings about acute gallbladder problems, increased heart rate, and suicidal thoughts, Trulicity warnings focus on severe gastrointestinal problems and discourage its use in patients with such conditions

This delayed gastric emptying contributes to prolonged feelings of fullness after meals, further aiding in weight management

Diagnosed with MASH (not just fatty liver/NAFLDmust be steatohepatitis) Moderate to advanced fibrosis (stages F2-F3, confirmed by FibroScan or biopsy) No cirrhosis (the approval is for noncirrhotic MASH only) Why This Matters for Coverage Bypass weight loss exclusions: Plans that exclude obesity drugs may cover liver disease treatments Medicare Part D potential: Like the CV indication, MASH may provide a pathway around the weight loss drug exclusion Different PA criteria: Liver disease documentation (FibroScan, biopsy, liver enzymes) may be easier to obtain than weight loss program history Do You Have MASH